Only the loss-of-function but not the gain-of-function properties of mutant TP53 are critical for the sustained proliferation, survival and metastasis of a broad range of cancer cells [colon cancer]

The loss of mutant TP53 has no impact on the growth of patient derived colon cancer organoids in vivo Overall design: CRISPR/Cas9 was used to delete mutant TP53 patient derived colon cancer organoids, then the tumour growth was detected in the control organoids (3 samples) and its mutant TP53 deficient variant (3 samples) both in vivo.